Literature DB >> 11405121

Pathophysiology and treatment of IgA nephropathy in children.

N Yoshikawa1, R Tanaka, K Iijima.   

Abstract

IgA nephropathy is the most-common primary glomerulonephritis worldwide, and about 20%-50% of patients develop progressive renal failure. The pathogenesis is still unknown and treatment has not yet been established. Knowledge concerning childhood IgA nephropathy has expanded greatly in the last 10 years, and its importance as the major form of glomerulonephritis and major contributor to end-stage renal disease is also becoming apparent in children. This review focuses on the pathophysiology and treatment of IgA nephropathy in children.

Entities:  

Mesh：

Year:  2001        PMID： 11405121     DOI： 10.1007/s004670100582

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  29 in total

1.  Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy.

Authors:  Rakesh Bhattacharjee; G Filler
Journal:  Pediatr Nephrol       Date:  2002-04       Impact factor: 3.714

2.  Long-term results of a randomized controlled trial in childhood IgA nephropathy.

Authors:  Koichi Kamei; Koichi Nakanishi; Shuichi Ito; Mari Saito; Mayumi Sako; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

3.  Epidemiological survey and clinical investigation of pediatric IgA nephropathy.

Authors:  Takayuki Shibano; Nobuaki Takagi; Kohei Maekawa; Hiromu Mae; Masuji Hattori; Yasuhiro Takeshima; Takakuni Tanizawa
Journal:  Clin Exp Nephrol       Date:  2015-06-04       Impact factor: 2.801

4.  Long-term outcome 19 years after childhood IgA nephritis: a retrospective cohort study.

Authors:  Jaana Ronkainen; Marja Ala-Houhala; Helena Autio-Harmainen; Timo Jahnukainen; Olli Koskimies; Jussi Merenmies; Jukka Mustonen; Timo Ormälä; Juha Turtinen; Matti Nuutinen
Journal:  Pediatr Nephrol       Date:  2006-07-13       Impact factor: 3.714

Review 5.  Steroid therapy in children with IgA nephropathy.

Authors:  Alexandra Cambier; Olivia Boyer; Georges Deschenes; James Gleeson; Anne Couderc; Julien Hogan; Thomas Robert
Journal:  Pediatr Nephrol       Date:  2019-02-18       Impact factor: 3.714

6.  Validity of the Oxford classification of IgA nephropathy in children.

Authors:  Yuko Shima; Koichi Nakanishi; Taketsugu Hama; Hironobu Mukaiyama; Hiroko Togawa; Yuya Hashimura; Hiroshi Kaito; Mayumi Sako; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2011-12-02       Impact factor: 3.714

7.  Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.

Authors:  Koichi Kamei; Koichi Nakanishi; Shuichi Ito; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Kandai Nozu; Kazumoto Iijima; Yuko Shima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2014-12-10       Impact factor: 3.714

8.  Effects of cyclosporin A therapy combined with steroids and angiotensin converting enzyme inhibitors on childhood IgA nephropathy.

Authors:  Jae Il Shin; Beom Jin Lim; Pyung Kil Kim; Jae Seung Lee; Hyeon Joo Jeong; Ji Hong Kim
Journal:  J Korean Med Sci       Date:  2010-04-22       Impact factor: 2.153

Review 9.  Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents.

Authors:  Siegtraut Dorothea Herder; Ernst Weber; Almuth Winkemann; Christoph Herder; Hartmut Morck
Journal:  Pediatr Nephrol       Date:  2010-05       Impact factor: 3.714

10.  Incidence of pediatric IgA nephropathy.

Authors:  Yasushi Utsunomiya; Takayuki Koda; Tadashi Kado; Sinichi Okada; Atsushi Hayashi; Susumu Kanzaki; Tsunakiyo Kasagi; Hiroshi Hayashibara; Teruo Okasora
Journal:  Pediatr Nephrol       Date:  2003-04-29       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.